


CPA
GAU 1646 #9
1-777

Please type a plus sign (+) inside this box → +

PTO/SB/29 (2/98)

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing. Check Box, if applicable
(Only for Continuation or Divisional applications under 37 CFR § 1.53(d)) ☐ Duplicate

Address to: Assistant Commissioner for Patents Box CPA Washington, D.C. 20231	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Attorney Docket No.</td> <td>PF466</td> </tr> <tr> <td>First Named Inventor</td> <td>Moore, Paul</td> </tr> <tr> <td>Examiner Name</td> <td>Brannock, M.</td> </tr> <tr> <td>Group/Art Unit</td> <td>1646</td> </tr> <tr> <td>Express Mail Label No.</td> <td></td> </tr> </table>	Attorney Docket No.	PF466	First Named Inventor	Moore, Paul	Examiner Name	Brannock, M.	Group/Art Unit	1646	Express Mail Label No.	
Attorney Docket No.	PF466										
First Named Inventor	Moore, Paul										
Examiner Name	Brannock, M.										
Group/Art Unit	1646										
Express Mail Label No.											

This is a request for a ☒ continuation or ☐ divisional application under 37 C.F.R. § 1.53(d), (continued prosecution application (CPA)) of prior application number: 09/263,626 filed on March 5, 1999 entitled Cytokine Receptor Common Gamma Chain Like

NOTES

Filing Qualifications: the prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR § 1.51(b), or (2) the national stage of an international application in compliance with 35 USC 371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 USC § 154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.

C-I-P Not Permitted: A continuation-in-part application cannot be filed as a CPA under 37 CFR § 1.53(d), but must be filed under 37 CFR § 1.53(b).

Express Abandonment of Prior Application: the filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR § 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

Access to Prior Application: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 USC 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR § 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 USC 120 Statement: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 USC 120 and to every application assigned the application number identified in such request. 37 CFR § 1.78(a).

1. ☐ Enter the unentered amendment previously filed on _____ under 37 C.F.R. § 1.116 in the prior nonprovisional application.
2. ☒ A preliminary amendment is enclosed.
3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 C.F.R. § 1.53(d)(4).
 - a. ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application;
 - b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. ☐ Information Disclosure Statement (IDS) is enclosed.
 - a. ☐ PTO-1449
 - b. ☐ Copies of IDS Citations

06/05/2000 EHAHOND 00000047 083425 09263626

01 FC:131 690.00 CH
02 FC:102 468.00 CH
03 FC:103 810.00 CH

RECEIVED
 JUN - 7 2000
 TC 1600 MAIL ROOM

Please type a plus sign (+) inside this box → +

PTO/SB/29 (2/98)

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TYPE	NO. FILE	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	65	-20	45	\$18.00 each	810.00
Independent	9	-3	6	\$78.00 each	468.00
Minimum Fee					690.00
Multiple Dependency Fee if applicable (\$260.00)					
Total Filing Fee					\$1,968.00

6. ☐ Small entity status:
- ☐ A small entity statement is enclosed, if (b) and (c) do not apply.
 - ☐ A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
 - ☐ Is no longer claimed.
7. ☒ The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 08-3425:
- ☒ Fees required under 37 CFR § 1.16
 - ☐ Fees required under 37 CFR § 1.17
 - ☐ Fees required under 37 CFR § 1.18
8. ☐ A check in the amount of \$ _____ is enclosed.
9. ☒ Other: Associate Power of Attorney
Petition for Extension of Time for two months

NOTE: The prior applications' correspondence address with carry over to this CPA UNLESS a new correspondence address is provided below.

10. NEW CORRESPONDENCE ADDRESS			
Name	Michele M. Wales, Esq., Attorney for Applicants Human Genome Sciences, Inc.		
Address	9410 Key West Avenue		
City	Rockville	State	MD Zip Code 20850
Country	US	Telephone	301-610-5772 Fax 301-309-8439

11. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
Name (Print/Type)	Michele M. Wales
Signature	
Registration No. (Attorney/Agent)	43,975
Date	June 2, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

B/10
7-27
6/20/00

In re application of: Moore et al.

Application Serial No.: 09/263,626

Filed: March 5, 1999

For: **Cytokine Receptor Common
Gamma Chain Like**



Art Unit: 1646

Examiner: Brannock, M.

Attorney Docket No.: PF466

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated 3 January, 2000, (Paper No. 6), Applicants hereby request that the following amendments and remarks be entered into the above-identified application. Applicants submit concurrently herewith: (a) Exhibits A-B; (b) a Petition for Extension of Time for two (2) months, up to and including June 3, 2000; (c) an Associate Power of Attorney; and (d) a Continued Prosecution Application Request Transmittal.

In the Specification:

Please amend the specification as follows:

At page 3, lines 9-10, please delete "Tabular representation of the data summarized graphically in Figure 3 can be found in Table 1." and insert

--The data presented in Figure 3 are also represented in tabular form in Table 1. The column headings refer to features of the amino acid sequence presented in Figure 3, and Table 1. Column 1, "Res," provides the amino acid residue of SEQ ID NO:2 and Figures 1A-1B and column 2, "Pos," provides the position of the corresponding residue within SEQ ID NO:2 and Figures 1A-1B. Column 3, "Garni...Alpha," provides the predicted Garnier-Robson Alpha Regions. Column 4, "Chou...Alpha," provides the predicted Chou-Fasman Alpha Regions. "Garni...Beta," column 5, provides the predicted Garnier-Robson Beta Regions. "Chou...Beta," column 6, shows the predicted Chou-Fasman Beta Regions. Column 7, "Garni...Turn," shows the predicted Garnier-Robson Turn Regions.

B1